Yüklüyor......
4CPS-013 Discontinuation of sodium-glucose co-transporter 2 inhibitors due to recurrent genitourinary infections
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in patients with type-2 diabetes (T2DM), either alone or in combination with other anti-diabetic drugs, when these medicines together with exercise and diet do not provide adequate control of the diabetes. Dapagliflozin, empagli...
Kaydedildi:
| Yayımlandı: | Eur J Hosp Pharm |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Group
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535808/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.104 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|